Tango Therapeutics Q1 Earnings Miss Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2026
0mins
Source: seekingalpha
Tango Therapeutics' stock fell sharply, hitting a 20-day low amid broader market declines.
The company's Q1 GAAP EPS of -$0.32 missed expectations by $0.01, highlighting ongoing profitability challenges. Additionally, despite holding $379.8 million in cash reserves, investor sentiment remains cautious, particularly given the stock's status as one of the most heavily shorted in the market.
This earnings miss may lead to further scrutiny of Tango's future performance and investor confidence, especially as the market continues to show weakness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TNGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TNGX
Wall Street analysts forecast TNGX stock price to fall
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 20.000
Low
12.00
Averages
13.67
High
15.00
Current: 20.000
Low
12.00
Averages
13.67
High
15.00
About TNGX
Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. The Company is focused on clinical development of two methylthioadenosine phosphorylase (MTAP)-deleted selective PRMT5 inhibitors: vopimetostat (TNG462) for non-CNS cancers, both as a monotherapy and in combination with RAS inhibitors, and TNG456, brain-penetrant protein arginine methyltransferase 5 (PRMT5) inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of the Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RTW Investments Increases Stake in Tango Therapeutics
- Share Increase: RTW Investments acquired 11,809,392 shares of Tango Therapeutics last quarter, with an estimated transaction value of $164.37 million, reflecting the firm's confidence in the biotechnology sector amid rising stock prices.
- Position Value Growth: This transaction increased RTW's quarter-end position value in Tango to $278.25 million, a rise of $265.04 million from the previous quarter, indicating a strategic investment approach in biotechnology.
- Financial Flexibility: Tango Therapeutics ended the first quarter with $379.8 million in cash and cash equivalents, which is expected to fund operations into 2028, showcasing the company's potential in advancing precision cancer therapies.
- R&D Outlook: Tango's lead candidate vopimetostat shows promising early results in ongoing combination studies targeting specific cancers, with management optimistic about upcoming clinical data, which could create significant value for the company.
See More
RTW Investments Acquires 11.8 Million Shares of Tango Therapeutics
- Major Acquisition: On May 15, 2026, RTW Investments disclosed the acquisition of 11,809,392 shares of Tango Therapeutics, valued at approximately $164.37 million, indicating strong confidence in the company's future prospects.
- Increased Stake: This acquisition raises RTW's stake in Tango to about 3%, reflecting a strategic positioning in the biotechnology sector, particularly in the promising field of precision medicine.
- Improved Financial Position: RTW's quarter-end position value increased by $265.04 million, indicating contributions from both the additional shares and stock price appreciation, showcasing market optimism regarding Tango's future developments.
- Future Growth Potential: Tango's lead candidate, vopimetostat, shows robust enrollment in ongoing combination studies targeting MTAP-deleted pancreatic and lung cancers, with initial safety and efficacy data expected later this year, further bolstering investor confidence.
See More
Boxer Capital Acquires $17.55 Million Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026 for an estimated $17.55 million, indicating strong confidence in the company, particularly as its stock has surged 250% over the past year.
- Quarter-End Position Value: As of March 31, 2026, Boxer Capital's position in Corvus was valued at $16.09 million, reflecting an active investment strategy amidst stock price fluctuations, further solidifying its standing in the biotech sector.
- Financial Overview: Corvus Pharmaceuticals ended Q1 2026 with $236.7 million in cash and marketable securities, with management stating that this funding will support operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: Corvus is conducting a Phase 2 trial expected to enroll approximately 200 patients, with preliminary data showing that 75% of patients maintained effective responses after treatment cessation, indicating potential in immune modulation that may attract further investor interest.
See More
Tango Therapeutics Stock Recovery Opportunity Amid Analyst Upgrades
- Analyst Optimism: Leerink raised its price target for Tango Therapeutics from $28 to $55, implying a 184% upside potential from current levels, reflecting strong confidence in the company's future, especially ahead of key pancreatic cancer data.
- Revenue Expectation Adjustments: Mizuho increased its price target from $20 to $30 while maintaining an 'Outperform' rating, primarily based on raised expectations for front-line pancreatic ductal adenocarcinoma revenue, indicating a positive market sentiment towards TNGX.
- Impact of Financing Activities: Wedbush raised its price target from $19 to $33, keeping an 'Outperform' rating, citing progress in the development of vopimetostat and recent financing activities, which demonstrate market recognition of the company's R&D capabilities.
- Quarterly Earnings Miss: Despite Tango Therapeutics reporting zero revenue in Q1, missing Wall Street expectations, analysts remain optimistic about its future development, reflecting confidence in the company's long-term potential.
See More
Tango Therapeutics Q1 Earnings Miss Expectations
- Earnings Performance: Tango Therapeutics reported a Q1 GAAP EPS of -$0.32, missing expectations by $0.01, indicating ongoing challenges in profitability that may affect investor confidence.
- Cash Reserves: As of March 31, 2026, the company held $379.8 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2028, ensuring continued investment in R&D and operations.
- Market Reaction: Despite the company's promise regarding PRMT5, there is a lack of strong buying interest in Tango Therapeutics' latest rally, reflecting cautious sentiment among investors regarding the company's future prospects.
- Short Selling Pressure: Tango Therapeutics is listed among the most heavily shorted stocks in the market, which may put downward pressure on its stock price, necessitating close attention to market sentiment's potential impact on the company's valuation.
See More
Tango Therapeutics Grants Stock Options and RSUs to Executives
- Executive Compensation Incentive: On May 1, 2026, Tango Therapeutics granted CFO Matthew Gall 240,000 stock options and 40,000 restricted stock units (RSUs), aimed at attracting and retaining key talent through equity incentives, thereby enhancing the long-term commitment of the management team.
- New Employee Inducement: The company also awarded a new employee 199,650 stock options and 33,250 RSUs, reflecting Tango Therapeutics' focus on attracting top talent through equity awards under its 2023 Inducement Plan to support company growth.
- Option Exercise Price Set: The exercise price for all granted options is set at $20.98 per share, equal to the closing price on May 1, 2026, which helps align the incentive measures with shareholder interests and promotes long-term growth in the company's stock price.
- Grant Terms and Conditions: These options and RSUs will vest over four and three years respectively, ensuring that employees remain in their positions on each vesting date, thereby enhancing retention rates and driving overall company performance.
See More
RTW Investments Increases Stake in Tango Therapeutics
- Share Increase: RTW Investments acquired 11,809,392 shares of Tango Therapeutics last quarter, with an estimated transaction value of $164.37 million, reflecting the firm's confidence in the biotechnology sector amid rising stock prices.
- Position Value Growth: This transaction increased RTW's quarter-end position value in Tango to $278.25 million, a rise of $265.04 million from the previous quarter, indicating a strategic investment approach in biotechnology.
- Financial Flexibility: Tango Therapeutics ended the first quarter with $379.8 million in cash and cash equivalents, which is expected to fund operations into 2028, showcasing the company's potential in advancing precision cancer therapies.
- R&D Outlook: Tango's lead candidate vopimetostat shows promising early results in ongoing combination studies targeting specific cancers, with management optimistic about upcoming clinical data, which could create significant value for the company.
See More
RTW Investments Acquires 11.8 Million Shares of Tango Therapeutics
- Major Acquisition: On May 15, 2026, RTW Investments disclosed the acquisition of 11,809,392 shares of Tango Therapeutics, valued at approximately $164.37 million, indicating strong confidence in the company's future prospects.
- Increased Stake: This acquisition raises RTW's stake in Tango to about 3%, reflecting a strategic positioning in the biotechnology sector, particularly in the promising field of precision medicine.
- Improved Financial Position: RTW's quarter-end position value increased by $265.04 million, indicating contributions from both the additional shares and stock price appreciation, showcasing market optimism regarding Tango's future developments.
- Future Growth Potential: Tango's lead candidate, vopimetostat, shows robust enrollment in ongoing combination studies targeting MTAP-deleted pancreatic and lung cancers, with initial safety and efficacy data expected later this year, further bolstering investor confidence.
See More
Boxer Capital Acquires $17.55 Million Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026 for an estimated $17.55 million, indicating strong confidence in the company, particularly as its stock has surged 250% over the past year.
- Quarter-End Position Value: As of March 31, 2026, Boxer Capital's position in Corvus was valued at $16.09 million, reflecting an active investment strategy amidst stock price fluctuations, further solidifying its standing in the biotech sector.
- Financial Overview: Corvus Pharmaceuticals ended Q1 2026 with $236.7 million in cash and marketable securities, with management stating that this funding will support operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: Corvus is conducting a Phase 2 trial expected to enroll approximately 200 patients, with preliminary data showing that 75% of patients maintained effective responses after treatment cessation, indicating potential in immune modulation that may attract further investor interest.
See More
Tango Therapeutics Stock Recovery Opportunity Amid Analyst Upgrades
- Analyst Optimism: Leerink raised its price target for Tango Therapeutics from $28 to $55, implying a 184% upside potential from current levels, reflecting strong confidence in the company's future, especially ahead of key pancreatic cancer data.
- Revenue Expectation Adjustments: Mizuho increased its price target from $20 to $30 while maintaining an 'Outperform' rating, primarily based on raised expectations for front-line pancreatic ductal adenocarcinoma revenue, indicating a positive market sentiment towards TNGX.
- Impact of Financing Activities: Wedbush raised its price target from $19 to $33, keeping an 'Outperform' rating, citing progress in the development of vopimetostat and recent financing activities, which demonstrate market recognition of the company's R&D capabilities.
- Quarterly Earnings Miss: Despite Tango Therapeutics reporting zero revenue in Q1, missing Wall Street expectations, analysts remain optimistic about its future development, reflecting confidence in the company's long-term potential.
See More
Tango Therapeutics Q1 Earnings Miss Expectations
- Earnings Performance: Tango Therapeutics reported a Q1 GAAP EPS of -$0.32, missing expectations by $0.01, indicating ongoing challenges in profitability that may affect investor confidence.
- Cash Reserves: As of March 31, 2026, the company held $379.8 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2028, ensuring continued investment in R&D and operations.
- Market Reaction: Despite the company's promise regarding PRMT5, there is a lack of strong buying interest in Tango Therapeutics' latest rally, reflecting cautious sentiment among investors regarding the company's future prospects.
- Short Selling Pressure: Tango Therapeutics is listed among the most heavily shorted stocks in the market, which may put downward pressure on its stock price, necessitating close attention to market sentiment's potential impact on the company's valuation.
See More
Tango Therapeutics Grants Stock Options and RSUs to Executives
- Executive Compensation Incentive: On May 1, 2026, Tango Therapeutics granted CFO Matthew Gall 240,000 stock options and 40,000 restricted stock units (RSUs), aimed at attracting and retaining key talent through equity incentives, thereby enhancing the long-term commitment of the management team.
- New Employee Inducement: The company also awarded a new employee 199,650 stock options and 33,250 RSUs, reflecting Tango Therapeutics' focus on attracting top talent through equity awards under its 2023 Inducement Plan to support company growth.
- Option Exercise Price Set: The exercise price for all granted options is set at $20.98 per share, equal to the closing price on May 1, 2026, which helps align the incentive measures with shareholder interests and promotes long-term growth in the company's stock price.
- Grant Terms and Conditions: These options and RSUs will vest over four and three years respectively, ensuring that employees remain in their positions on each vesting date, thereby enhancing retention rates and driving overall company performance.
See More
